A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2018
At a glance
- Drugs GSK 1795091 (Primary) ; GSK 3174998 (Primary)
- Indications Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 11 Oct 2018 Planned number of patients changed from 54 to 162.
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.